NDC 63323-285-55 - Naropin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-285
- Requested NDC
- 63323-285-55
- Package NDCs from labels
- 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67
- Manufacturer
- Fresenius Kabi USA, LLC
- Effective date
- 2024-08-15
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2024-08-15 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS | 2024-08-06 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2024-07-10 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - APP Pharmaceuticals, LLC | Fresenius Kabi Norge AS | APP Pharmaceuticals, LLC | Fresenius Kabi Norge AS | 2011-09-15 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-285-01 | Naropin | 10 mL in 1 AMPULE | INJECTION, SOLUTION | 10 | 27 | |
| 63323-285-02 | Naropin | 100 mL in 1 BAG | INJECTION, SOLUTION | 100 | 27 | |
| 63323-285-03 | Naropin | 10 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 10 | 27 | |
| 63323-285-04 | Naropin | 200 mL in 1 BAG | INJECTION, SOLUTION | 200 | 27 | |
| 63323-285-06 | Naropin | 20 mL in 1 AMPULE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-285-07 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-285-10 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-285-13 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-285-20 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-285-23 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-285-51 | Naropin | 100 mL in 1 BOTTLE | INJECTION, SOLUTION | 100 | 27 | |
| 63323-285-57 | Naropin | 200 mL in 1 BOTTLE | INJECTION, SOLUTION | 200 | 27 | |
| 63323-285-61 | Naropin | 24 in 1 CASE | INJECTION, SOLUTION | 24 | 27 | |
| 63323-285-63 | Naropin | 24 in 1 CASE | INJECTION, SOLUTION | 24 | 27 | |
| 63323-285-64 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 27 | |
| 63323-285-65 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 27 | |
| 63323-285-55 | Naropin | 100 mL in 1 BOTTLE | INJECTION, SOLUTION | 100 | 8 | |
| 63323-285-67 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 8 | |
| 63323-285-28 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 6 | |
| 63323-285-41 | Naropin | 20 mL in 1 VIAL, SINGLE-USE | INJECTION, SOLUTION | 20 | 6 | |
| 63323-285-53 | Naropin | 100 mL in 1 BOTTLE | INJECTION, SOLUTION | 100 | 6 | |
| 63323-285-59 | Naropin | 200 mL in 1 BOTTLE | INJECTION, SOLUTION | 200 | 6 | |
| 63323-285-68 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 6 | |
| 63323-285-73 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-285 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 27 | Current NDC, Legacy NDC, 16 package rows | 20240814_23d2d448-a744-4877-9f2d-7e57c198da89.zip |
| 63323-285 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 8 | Current NDC, Legacy NDC, 2 package rows | 20240817_c6613708-c1f7-4f5c-91a3-ebbc1d7905c6.zip |
| 63323-285 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 6 | Current NDC, Legacy NDC, 6 package rows | 20240829_dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7.zip |
DailyMed Billing Units#
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SODIUM CHLORIDE | SODIUM CHLORIDE | Baxter Healthcare Corporation | b3b4b176-41f0-4ca8-90d4-3fba5707564a | 2014-02-21 | 451W47IQ8X | |
| TIS-U-SOL | SODIUM CHLORIDE, POTASSIUM CHLORIDE, MAGNESIUM SULFATE, SODIUM PHOSPHATE, AND POTASSIUM PHOSPHATE | Baxter Healthcare Corporation | 9da4121f-d62d-4da4-8dfb-0494da16015f | 2014-02-21 | 451W47IQ8X | |
| Ringers | SODIUM CHLORIDE, CALCIUM CHLORIDE, POTASSIUM CHLORIDE, | Baxter Healthcare Corporation | e1953d54-818d-46a6-8532-518ebae6d84e | 2012-06-13 | 451W47IQ8X | |
| Lactated Ringers | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE | Baxter Healthcare Corporation | f09f80bf-2f8b-4420-865d-aec2d5e5cd4d | 2012-06-12 | 451W47IQ8X | |
| c5a1ce28-2785-45e2-ad20-32dd83b626ea | f27790b5-cdb9-4fd2-b575-70686a5cbb58 | 2011-09-15 | Warnings, Adverse reactions | c5a1ce28-2785-45e2-ad20-32dd83b626ea f27790b5-cdb9-4fd2-b575-70686a5cbb58 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.